Interventional Cardiology - Coronary Stents

The Cre8TM polymer-free DES embodies the most advanced DES technologies to treat coronary vascular disease. Its unique distinctive features - Abluminal Reservoir Technology, Amphilimus Formulation and Bio Inducer Surface - make Cre8TM the only very effective Polymer-Free DES today available. In the NEXT study, an international prospective randomized clinical trial, it resulted being statistically superior to TAXUSTM Libertè with respect to in-stent late lumen loss (0.14 mm Cre8TM vs. 0.34 mm Taxus, p<0.0001).

The proprietary Abluminal Reservoir Technology (ART) provides a consistent drug loading onto the stent platform, thus enabling a controlled and directed elution exclusively targeted to the vessel wall.
The innovative Amphilimus™ formulation, that is Sirolimus formulated with an organic acid, is the first known use of a carrier to enhance drug bioavailability and drug distribution to the entire vessel wall.
The Bio Inducer Surface, a second generation integral pure carbon coating, demonstrates excellent results in terms of stent endothelialization and struts coverage. The use of the Bio Inducer Surface onto the Cre8TM Polymer-Free DES enables faster DES endothelialisation and reduces device thrombogenicity risk.

  Download the brochure

Avantgarde is the expression of over 15 years of research and innovation in bio and haemocompatible coatings pursuing patient safety.
Recent studies evidence that the physical and chemical properties of pure carbon coatings are strictly related, by virtue of their closeness, to the structure of diamonds.
The Bio Inducer Surface is the latest improvement in pure carbon coatings, advancing this technology towards the most inert and bio/haemocompatible material on earth: diamonds.

  Download the brochure

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

Clinical results from more than 500 patients with bifurcation lesions have consistently demonstrated target lesion revascularization (TLR) rates of less than four percent.
 

  Download the brochure